Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AKBA Akebia Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: AKBA
Price (delayed)
$2.45
Market cap
$643.46M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.22
Enterprise value
$578.72M
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is
Highlights
The equity has soared by 190% year-on-year and by 150% since the previous quarter
The company's quick ratio has surged by 86% YoY and by 79% QoQ
AKBA's debt is down by 47% year-on-year but it is up by 15% since the previous quarter
AKBA's net income is up by 35% from the previous quarter but it is down by 5% YoY
Key stats
What are the main financial stats of AKBA
Market
Valuations
Earnings
Shares outstanding
262.64M
Market cap
$643.46M
Enterprise value
$578.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
23.55
Price to sales (P/S)
3.12
EV/EBIT
N/A
EV/EBITDA
53.23
EV/Sales
3.13
Revenue
$184.91M
Gross profit
$125.71M
Operating income
-$18.81M
Net income
-$45.31M
EBIT
-$21.86M
EBITDA
$10.87M
Free cash flow
-$34.69M
Per share
Balance sheet
Liquidity
EPS
-$0.22
EPS diluted
-$0.22
Free cash flow per share
-$0.15
Book value per share
$0.1
Revenue per share
$0.79
TBVPS
$1.07
Total assets
$310.19M
Total liabilities
$285.6M
Debt
$48.63M
Equity
$24.58M
Working capital
$112.56M
Debt to equity
1.98
Current ratio
2.23
Quick ratio
1.92
Net debt/EBITDA
-5.95
Margins
Efficiency
Dividend
EBITDA margin
5.9%
Gross margin
68%
Net margin
-24.5%
Operating margin
-10.2%
Return on assets
-18.9%
Return on equity
N/A
Return on invested capital
-30.2%
Return on capital employed
-10%
Return on sales
-11.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AKBA stock price
How has the Akebia Therapeutics stock price performed over time
Intraday
-1.21%
1 week
-0.41%
1 month
33.88%
1 year
99.19%
YTD
28.95%
QTD
27.6%
Financial performance
How have Akebia Therapeutics's revenue and profit performed over time
Revenue
$184.91M
Gross profit
$125.71M
Operating income
-$18.81M
Net income
-$45.31M
Gross margin
68%
Net margin
-24.5%
The operating margin has soared by 65% from the previous quarter and by 41% YoY
The operating income has surged by 60% since the previous quarter and by 42% year-on-year
AKBA's net margin is up by 43% since the previous quarter but it is down by 7% year-on-year
AKBA's net income is up by 35% from the previous quarter but it is down by 5% YoY
Price vs fundamentals
How does AKBA's price correlate with its fundamentals
Growth
What is Akebia Therapeutics's growth rate over time
Valuation
What is Akebia Therapeutics stock price valuation
P/E
N/A
P/B
23.55
P/S
3.12
EV/EBIT
N/A
EV/EBITDA
53.23
EV/Sales
3.13
Akebia Therapeutics's EPS has increased by 33% from the previous quarter and by 4.3% YoY
The equity has soared by 190% year-on-year and by 150% since the previous quarter
The price to sales (P/S) is 95% more than the 5-year quarterly average of 1.6 and 56% more than the last 4 quarters average of 2.0
Akebia Therapeutics's revenue has increased by 15% QoQ
Efficiency
How efficient is Akebia Therapeutics business performance
Akebia Therapeutics's ROS has soared by 63% from the previous quarter and by 39% YoY
The return on invested capital has surged by 53% since the previous quarter and by 19% year-on-year
The ROA has grown by 41% from the previous quarter but it has contracted by 5% YoY
Dividends
What is AKBA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AKBA.
Financial health
How did Akebia Therapeutics financials performed over time
AKBA's total assets is 9% greater than its total liabilities
The company's quick ratio has surged by 86% YoY and by 79% QoQ
Akebia Therapeutics's current ratio has surged by 58% QoQ and by 31% YoY
AKBA's debt is 98% greater than its equity
The equity has soared by 190% year-on-year and by 150% since the previous quarter
The debt to equity has surged by 159% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.